• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿尔茨海默病弥散和核心淀粉样-β斑块中 PiB 和 flutemetamol 的死后分析。

Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.

机构信息

Geriatric Research Education and Clinical Center, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.

Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.

出版信息

Acta Neuropathol. 2020 Oct;140(4):463-476. doi: 10.1007/s00401-020-02175-1. Epub 2020 Aug 9.

DOI:10.1007/s00401-020-02175-1
PMID:32772265
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7498488/
Abstract

Specificity and sensitivity of positron emission tomography (PET) radiopharmaceuticals targeting fibrillar amyloid-β (Aβ) deposits is high for detection of neuritic Aβ plaques, a mature form of Aβ deposits which often have dense Aβ core (i.e., cored plaques). However, imaging-to-autopsy validation studies of amyloid PET radioligands have identified several false positive cases all of which had mainly diffuse Aβ plaques (i.e., plaques without neuritic pathology or dense amyloid core), and high amyloid PET signal was reported in the striatum where diffuse plaques predominate in Alzheimer's disease (AD). Relative contributions of different plaque types to amyloid PET signal is unclear, particularly in neocortical areas where they are intermixed in AD. In vitro binding assay and autoradiography were performed using [H]flutemetamol and [H]Pittsburgh Compound-B (PiB) in frozen brain homogenates from 30 autopsy cases including sporadic AD and non-AD controls with a range of brain Aβ burden and plaque density. Fixed tissue sections of frontal cortex and caudate from 10 of the AD cases were processed for microscopy using fluorescent derivatives of flutemetamol (cyano-flutemetamol) and PiB (cyano-PiB) and compared to Aβ immunohistochemistry and pan-amyloid (X-34) histology. Using epifluorescence microscopy, percent area coverage and fluorescence output values of cyano-PiB- and cyano-flutemetamol-labeled plaques in two-dimensional microscopic fields were then calculated and combined to obtain integrated density measurements. Using confocal microscopy, we analysed total fluorescence output of the entire three-dimensional volume of individual cored plaques and diffuse plaques labeled with cyano-flutemetamol or cyano-PiB. [H]Flutemetamol and [H]PiB binding values in tissue homogenates correlated strongly and their binding pattern in tissue sections, as seen on autoradiograms, overlapped the pattern of Aβ-immunoreactive plaques on directly adjacent sections. Cyano-flutemetamol and cyano-PiB fluorescence was prominent in cored plaques and less so in diffuse plaques. Across brain regions and cases, percent area coverage of cyano-flutemetamol-labeled plaques correlated strongly with cyano-PiB-labeled and Aβ-immunoreactive plaques. For both ligands, plaque burden, calculated as percent area coverage of all Aβ plaque types, was similar in frontal cortex and caudate regions, while integrated density values were significantly greater in frontal cortex, which contained both cored plaques and diffuse plaques, compared to the caudate, which contained only diffuse plaques. Three-dimensional analysis of individual plaques labeled with either ligand showed that total fluorescence output of a single cored plaque was equivalent to total fluorescence output of approximately three diffuse plaques of similar volume. Our results indicate that [F]flutemetamol and [C]PiB PET signal is influenced by both diffuse plaques and cored plaques, and therefore is likely a function of plaque size and density of Aβ fibrils in plaques. Brain areas with large volumes/frequencies of diffuse plaques could yield [F]flutemetamol and [C]PiB PET retention levels comparable to brain regions with a lower volume/frequency of cored plaques.

摘要

正电子发射断层扫描(PET)放射性药物针对纤维状淀粉样β(Aβ)沉积物的特异性和敏感性很高,可用于检测神经原纤维 Aβ斑块,这是 Aβ沉积物的成熟形式,通常具有密集的 Aβ核心(即有核斑块)。然而,淀粉样 PET 配体的成像-尸检验证研究已经确定了几个假阳性病例,这些病例都主要具有弥漫性 Aβ斑块(即没有神经原纤维病理学或密集 Aβ核心的斑块),并且在纹状体中报告了高淀粉样 PET 信号,在那里弥漫性斑块在阿尔茨海默病(AD)中占主导地位。不同斑块类型对淀粉样 PET 信号的相对贡献尚不清楚,特别是在 AD 中斑块相互混合的新皮质区域。使用 [H]flutemetamol 和 [H]Pittsburgh 化合物-B(PiB)在包括散发性 AD 和非 AD 对照的 30 例尸检病例的冷冻脑匀浆中进行了体外结合测定和放射自显影,这些病例的脑 Aβ负担和斑块密度范围广泛。从 10 例 AD 病例的额皮质和尾状核固定组织切片中,使用 flutemetamol(氰基-flutemetamol)和 PiB(氰基-PiB)的荧光衍生物进行显微镜处理,并与 Aβ免疫组织化学和全淀粉样(X-34)组织学进行比较。使用荧光显微镜,然后计算二维显微镜视野中氰基-PiB 和氰基-flutemetamol 标记斑块的面积覆盖率和荧光输出值,并将其组合以获得积分密度测量值。使用共聚焦显微镜,我们分析了用氰基-flutemetamol 或氰基-PiB 标记的单个有核斑块和弥漫性斑块的整个三维体积的总荧光输出。组织匀浆中的 [H]flutemetamol 和 [H]PiB 结合值相关性很强,其在组织切片中的结合模式(如放射自显影所见)与直接相邻切片中 Aβ-免疫反应性斑块的模式重叠。氰基-flutemetamol 和氰基-PiB 荧光在有核斑块中明显,在弥漫性斑块中则不明显。在整个大脑区域和病例中,氰基-flutemetamol 标记斑块的面积覆盖率与氰基-PiB 标记和 Aβ-免疫反应性斑块高度相关。对于两种配体,所有 Aβ 斑块类型的面积覆盖率计算的斑块负担在额皮质和尾状核区域相似,而整合密度值在包含有核斑块和弥漫性斑块的额皮质显著更高,与仅包含弥漫性斑块的尾状核相比。用任一配体标记的单个斑块的三维分析表明,单个有核斑块的总荧光输出相当于类似体积的三个弥漫性斑块的总荧光输出。我们的结果表明,[F]flutemetamol 和 [C]PiB PET 信号受弥漫性斑块和有核斑块的影响,因此可能是 Aβ纤维斑块的大小和密度的函数。具有大体积/弥漫性斑块频率的脑区可能会产生与具有较低体积/有核斑块频率的脑区相当的 [F]flutemetamol 和 [C]PiB PET 保留水平。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69b/7498488/b4a4617964fc/401_2020_2175_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69b/7498488/70fc6f86aa1f/401_2020_2175_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69b/7498488/9425b9fcf46c/401_2020_2175_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69b/7498488/201b114f4d80/401_2020_2175_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69b/7498488/4a89543d2cb5/401_2020_2175_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69b/7498488/f12e2b77c37e/401_2020_2175_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69b/7498488/8f50c8d04599/401_2020_2175_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69b/7498488/7b417c3dfc82/401_2020_2175_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69b/7498488/31ce5ba24ae7/401_2020_2175_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69b/7498488/b3d789056257/401_2020_2175_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69b/7498488/b4a4617964fc/401_2020_2175_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69b/7498488/70fc6f86aa1f/401_2020_2175_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69b/7498488/9425b9fcf46c/401_2020_2175_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69b/7498488/201b114f4d80/401_2020_2175_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69b/7498488/4a89543d2cb5/401_2020_2175_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69b/7498488/f12e2b77c37e/401_2020_2175_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69b/7498488/8f50c8d04599/401_2020_2175_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69b/7498488/7b417c3dfc82/401_2020_2175_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69b/7498488/31ce5ba24ae7/401_2020_2175_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69b/7498488/b3d789056257/401_2020_2175_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69b/7498488/b4a4617964fc/401_2020_2175_Fig10_HTML.jpg

相似文献

1
Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.阿尔茨海默病弥散和核心淀粉样-β斑块中 PiB 和 flutemetamol 的死后分析。
Acta Neuropathol. 2020 Oct;140(4):463-476. doi: 10.1007/s00401-020-02175-1. Epub 2020 Aug 9.
2
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.阿尔茨海默病典型病例中体内PiB-PET淀粉样蛋白成像的尸检相关性
Brain. 2008 Jun;131(Pt 6):1630-45. doi: 10.1093/brain/awn016. Epub 2008 Mar 12.
3
Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.注射氟曲美他酚 F18 后β-淀粉样蛋白 PET 成像的死后组织病理学基础。
Acta Neuropathol Commun. 2016 Dec 12;4(1):130. doi: 10.1186/s40478-016-0399-z.
4
Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease.比较常染色体显性遗传和迟发性阿尔茨海默病患者淀粉样-β斑块负担与生前 PiB PET。
Acta Neuropathol. 2021 Oct;142(4):689-706. doi: 10.1007/s00401-021-02342-y. Epub 2021 Jul 28.
5
11C-PiB PET can underestimate brain amyloid-β burden when cotton wool plaques are numerous.11C-PiB PET 当棉绒斑较多时可能会低估脑内淀粉样蛋白-β负担。
Brain. 2022 Jun 30;145(6):2161-2176. doi: 10.1093/brain/awab434.
6
Imaging of amyloid deposition in human brain using positron emission tomography and [18F]FACT: comparison with [11C]PIB.使用正电子发射断层扫描和[18F]FACT对人脑淀粉样蛋白沉积进行成像:与[11C]PIB的比较。
Eur J Nucl Med Mol Imaging. 2014 Apr;41(4):745-54. doi: 10.1007/s00259-013-2620-7.
7
Detection of Striatal Amyloid Plaques with [18F]flutemetamol: Validation with Postmortem Histopathology.用[18F]氟美妥莫尔检测纹状体淀粉样斑块:与尸检组织病理学对照验证
J Alzheimers Dis. 2016 Mar 31;52(3):863-73. doi: 10.3233/JAD-150732.
8
Estimation of amyloid distribution by [F]flutemetamol PET predicts the neuropathological phase of amyloid β-protein deposition.[F]氟替美莫 PET 对淀粉样蛋白分布的评估可预测淀粉样 β 蛋白沉积的神经病理学阶段。
Acta Neuropathol. 2018 Oct;136(4):557-567. doi: 10.1007/s00401-018-1897-9. Epub 2018 Aug 19.
9
Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study.早期 AD 病理学在一个 [C-11]PiB 阴性病例中的表现:PiB-淀粉样蛋白成像、生物化学和免疫组织化学研究。
Acta Neuropathol. 2012 Mar;123(3):433-47. doi: 10.1007/s00401-012-0943-2. Epub 2012 Jan 24.
10
Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques.体内 (11)C-PiB-PET 淀粉样蛋白成像与死后斑块区域匹配评估之间的相关性。
Acta Neuropathol. 2012 Dec;124(6):823-31. doi: 10.1007/s00401-012-1025-1. Epub 2012 Aug 5.

引用本文的文献

1
High-affinity transferrin receptor binding improves brain delivery of bispecific antibodies at tracer dose.高亲和力转铁蛋白受体结合可提高示踪剂量双特异性抗体的脑内递送。
Fluids Barriers CNS. 2025 Aug 21;22(1):86. doi: 10.1186/s12987-025-00693-2.
2
Joint spatial associations of amyloid beta and tau pathology in Down syndrome and preclinical Alzheimer's disease: Cross-sectional associations with early cognitive impairments.唐氏综合征和临床前阿尔茨海默病中β-淀粉样蛋白和tau病理的联合空间关联:与早期认知障碍的横断面关联
Alzheimers Dement. 2025 Jul;21(7):e70424. doi: 10.1002/alz.70424.
3
The striatum is an early, accurate indicator of amyloid burden using [C]PiB in Down syndrome: Comparison of two radiotracers.

本文引用的文献

1
Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography.使用淀粉样蛋白正电子发射断层扫描对β-淀粉样蛋白病理学进行分期
JAMA Neurol. 2019 Nov 1;76(11):1319-1329. doi: 10.1001/jamaneurol.2019.2214.
2
Abnormal Amyloid Load in Mild Cognitive Impairment: The Effect of Reducing the PiB-PET Threshold.轻度认知障碍中的异常淀粉样蛋白负荷:降低 PiB-PET 阈值的影响。
J Neuroimaging. 2019 Jul;29(4):499-505. doi: 10.1111/jon.12629. Epub 2019 May 10.
3
Centiloid scaling for quantification of brain amyloid with [F]flutemetamol using multiple processing methods.
在唐氏综合征中,纹状体是使用[C]PiB检测淀粉样蛋白负荷的早期、准确指标:两种放射性示踪剂的比较。
Alzheimers Dement. 2025 Apr;21(4):e70141. doi: 10.1002/alz.70141.
4
Autoradiographic comparison between [C]PiB and [F]AZD4694 in human brain tissue.人脑组织中[C]匹兹堡化合物B(PiB)与[F]AZD4694的放射自显影比较。
EJNMMI Res. 2025 Apr 1;15(1):30. doi: 10.1186/s13550-025-01216-8.
5
The neuropathologic basis for translational biomarker development in the macaque model of late-onset Alzheimer's disease.迟发性阿尔茨海默病猕猴模型中转化生物标志物开发的神经病理学基础。
J Alzheimers Dis. 2025 Apr;104(4):1243-1258. doi: 10.1177/13872877251323787. Epub 2025 Mar 17.
6
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.阿尔茨海默病淀粉样蛋白PET和脑脊液生物标志物临床应用的考量
Alzheimers Dement. 2025 Mar;21(3):e14528. doi: 10.1002/alz.14528.
7
Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.淀粉样蛋白和tau蛋白PET的更新后合理使用标准:阿尔茨海默病协会与核医学和分子影像学会工作组的报告
Alzheimers Dement. 2025 Jan;21(1):e14338. doi: 10.1002/alz.14338. Epub 2025 Jan 8.
8
The striatum is an early, accurate indicator of amyloid burden using [C]PiB in Down syndrome: comparison of two radiotracers.纹状体是唐氏综合征中使用[C]匹兹堡化合物B(PiB)检测淀粉样蛋白负荷的早期准确指标:两种放射性示踪剂的比较。
medRxiv. 2024 Dec 6:2024.12.04.24318526. doi: 10.1101/2024.12.04.24318526.
9
Stem cell therapy in Alzheimer's disease: current status and perspectives.阿尔茨海默病的干细胞治疗:现状与展望
Front Neurosci. 2024 Nov 21;18:1440334. doi: 10.3389/fnins.2024.1440334. eCollection 2024.
10
Predicting continuous amyloid PET values with CSF tau phosphorylation occupancies.利用 CSF tau 磷酸化占有率预测连续淀粉样蛋白 PET 值。
Alzheimers Dement. 2024 Sep;20(9):6365-6373. doi: 10.1002/alz.14132. Epub 2024 Jul 23.
使用多种处理方法,通过[F]氟代甲磺酸去甲肾上腺素进行脑淀粉样蛋白定量的百分度缩放。
EJNMMI Res. 2018 Dec 5;8(1):107. doi: 10.1186/s13550-018-0456-7.
4
Comparison of longitudinal Aβ in nondemented elderly and Down syndrome.比较非痴呆老年人与唐氏综合征患者的纵向 Aβ。
Neurobiol Aging. 2019 Jan;73:171-176. doi: 10.1016/j.neurobiolaging.2018.09.030. Epub 2018 Sep 27.
5
Infrequent false positive [F]flutemetamol PET signal is resolved by combined histological assessment of neuritic and diffuse plaques.不常见的假阳性[F]flutemetamol PET 信号通过神经原纤维和弥漫性斑块的联合组织学评估得到解决。
Alzheimers Res Ther. 2018 Jun 23;10(1):60. doi: 10.1186/s13195-018-0387-6.
6
In vivo staging of regional amyloid deposition.区域淀粉样蛋白沉积的体内分期
Neurology. 2017 Nov 14;89(20):2031-2038. doi: 10.1212/WNL.0000000000004643. Epub 2017 Oct 18.
7
Small-molecule PET Tracers for Imaging Proteinopathies.小分子 PET 示踪剂用于成像蛋白病。
Semin Nucl Med. 2017 Sep;47(5):553-575. doi: 10.1053/j.semnuclmed.2017.06.003. Epub 2017 Jul 13.
8
Imaging the ageing brain: identifying early disease or opening Pandora's box?对衰老大脑进行成像:是识别早期疾病还是打开潘多拉魔盒?
Lancet Neurol. 2017 Jun;16(6):411-413. doi: 10.1016/S1474-4422(17)30116-3. Epub 2017 Apr 26.
9
Defining imaging biomarker cut points for brain aging and Alzheimer's disease.定义脑老化和阿尔茨海默病的影像学生物标志物切点。
Alzheimers Dement. 2017 Mar;13(3):205-216. doi: 10.1016/j.jalz.2016.08.005. Epub 2016 Sep 30.
10
Detection of Striatal Amyloid Plaques with [18F]flutemetamol: Validation with Postmortem Histopathology.用[18F]氟美妥莫尔检测纹状体淀粉样斑块:与尸检组织病理学对照验证
J Alzheimers Dis. 2016 Mar 31;52(3):863-73. doi: 10.3233/JAD-150732.